Skip to main content
SpringerLink
Log in

Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts

  • Original Article
  • Cisplatin, Pharmacokinetics, Tissue Distribution, Cisplatin, DNA Adducts
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

The pharmacokinetics of platinum (Pt) and cisplatin (CDDP)-DNA adducts were studied in nude mice after single-dose CDDP treatments. Whole blood, serum, kidney, lever, testis, brain, and tumor were collected at different intervals after injection of CDP at different dose levels. Pt was measured with flameless atomic absorption spectrometry (FAAS) or adsorptive voltammetry (AdV) and CDDP-DNA adducts with quantitative immunohistochemistry. The drug was immediately absorbed into the blood circulation (peak serum Pt levels were reached within 5 min) after i.p. CDDP administration, and distribution into most tissues also occurred rapidly (tissue Pt levels peaked at 15 min). With a sampling period of 7 days there was a biphasic elimination of Pt from blood, serum, and tissues. In the brain the pharmacokinetics differed with a gradual accumulation of Pt occurring during the 1st week. Formation of CDDP-DNA adducts in tissues was a slower process, with maximal levels being achieved at between 30 min and 4 h after drug administration, followed by a steady state lasting for at least 24 h. Each tissue type had its specific immunohistochemical staining pattern of adducts. With escalating CDDP doses there was a linear, or almost linear, increase in Pt concentrations and CDDP-DNA adduct levels in all sample types examined. These results suggest that a fair estimation of the amount of drug in tumor and normal tissues can be made from analysis of serum Pt at a fixed time point after a single dose of CDDP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ali PA, Lewis DG, El-Sharkawi AM, Al-Sadhan FA, Evans CJ, Hancock DA, Dutton J (1993) Initial measurements of platinum concentration in head and neck tumors using X-ray fluorescence. Basic Life Sci 60: 281

    Google Scholar 

  2. Amlacher R, Böckel V, Mackowiak A, Stadeler M, Frankenberg D, Hoffmann H (1990) Distribution of cisplatin in tumor-free versus tumor bearing B6D2F1 mice. Arch Geschwulstforsch 60: 341

    Google Scholar 

  3. Andrews PA, Howell SB (1990) Cellular pharmacology of cisplatin: perspectives on mechanism of acquired resistance. Cancer Cells 2: 35

    Google Scholar 

  4. Bacus JW, Grace LJ (1987) Optical microscope system for standardized cell measurements and analyses. Appl Optics 26: 3280

    Google Scholar 

  5. Blommaert FA, Michael C, Terheggen PMAB, Muggia FM, Kortes V, Schornagel JH, Hart AAM, Engelse L den (1993) Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease response. Cancer Res 53: 5669

    Google Scholar 

  6. Boven E, Vijgh WJF van der, Nauta MM, Schlüper HMM, Pinedo HM (1985) Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts. Cancer Res 45: 86

    Google Scholar 

  7. Brady HR, Zeidel ML, Kone BC, Giebisch G, Gullans SR (1993) Differential actions of cisplatin on renal proximal tubule and inner medullary collecting duct cells. J Pharmacol Exp Ther 265: 1421

    Google Scholar 

  8. Campbell AB, Kalman SM, Jacobs C (1983) Plasma platinum levels: Relationship to cisplatin dose and nephrotoxicity. Cancer Treat Rep 67: 169

    Google Scholar 

  9. Desoize B, Marechal F, Millart H, Cattan A (1991) Correlation of clinical pharmacokinetic parameters of cisplatin with efficacy and toxicity. Biomed Pharmacother 45: 203

    Google Scholar 

  10. Esposito M, Vannozzi MO, Viale M, Pellecchia C, Merlo F, Cadoni A, Cafaggi S, Parodi B, Lerza R, Poirier MC (1993)cis-Diamminedichloroplatinum(II)-procaine pharmacokinetic interaction in mice bearing P388 leukemia. Anticancer Res 13: 1511

    Google Scholar 

  11. Fichtinger-Schepman AMJ, Veer JL van der, Hartog JHJ den, Lohman PHM, Reedijk J (1985) Adducts of the antitumor drugcis-diamminedichloroplatinum(II) with DNA: formation, identification and quantification. Biochemistry 24: 707

    Google Scholar 

  12. Fichtinger-Schepman AMJ, Vendrik CPJ, Dijk-Knijnenburg WCM van, Jong WH de, Minnen ACE van der, Claessen AME, Velde-Visser SD van der, Groot G de, Wubs KL, Steerenberg PA, Schornagel JH, Berends F (1989) Platinum concentration and DNA adduct levels in tumors and organs of cisplatin-treated LOU/M rats inoculated with cisplatin-sensitive or-resistant immunoglobulin M immunocytoma. Cancer Res 49: 2862

    Google Scholar 

  13. Fichtinger-Schepman AMJ, Velde-Visser SD van der, Dijk-Knijnenburg WCM van, Oosterom AT van der, Baan RA, Berends F (1990) Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissues of cancer patients receiving chemotherapy: comparison with in vitro adduct fromation. Cancer Res 50: 7887

    Google Scholar 

  14. Fulco RA, Vannozzi M, Collecchi P, Merlo F, Parodi B, Civalleri D, Esposito M (1990) Effect of normal saline on cisplatin pharmacokinetics and antitumor activity in mice bearing P388 leukemia. Anticancer Res 10: 1603

    Google Scholar 

  15. Johnsson A, Olsson C, Andersson H, Cavallin-Stahl E (1994) Evaluation of a method for quantitative immunohistochemical analysis of cisplatin-DNA adducts in tissues from nude mice. Cytometry 17: 142

    Google Scholar 

  16. Jonson R, Mattsson S, Unsgaard B (1988) A method for in vivo analysis of platinum after chemotherapy with cisplatin. Phys Med Biol 33: 847

    Google Scholar 

  17. Kataoka M, Kawamura M, Nishiyama Y, Fujii T, Mogami H, Itoh H, Akuta K, Akaboshi M, Kawai K, Hamamoto K (1993) Distribution of radiolabeledcis-diamminedichloroplatinum(II) on scintigraphic images in the tumor-bearing rabbit. Radiat Med 11: 173

    Google Scholar 

  18. Kubota T, Inoue S, Furukawa T, Ishibiki K, Kitajima M, Kawamura E, Hoffman RM (1993) Similarity of serum-tumor pharmacokinetics of antitumor agents in man and mice. Anticancer Res 13: 1481

    Google Scholar 

  19. Lange RC, Spencer RP, Harder HC (1973) The antitumor agent cis-Pt(NH3)2Cl2: distribution studies and dose calculation for 193mPt and 195mPt. J Nucl med 14: 191

    Google Scholar 

  20. Levi JA, Aroney RS, Dalley DN (1981) Haemolytic anaemia after cisplatin treatment. BMJ 282: 2003

    Google Scholar 

  21. Litterst CL, Gram TE, Dedrick RL, Leroy AF, Guarino AM (1976) Distribution and disposition of platinum following intravenous administration ofcis-diamminedichloroplatinum(II) (NSC 119875) to dogs. Cancer Res 36: 2340

    Google Scholar 

  22. Litterst CL, LeRoy AF, Guarino AM (1979) Disposition and distribution of platinum following parenteral administration ofcis-dichlorodiammineplatinum(II) to animals. Cancer Treat Rep 63: 1485

    Google Scholar 

  23. Los G (1990) Experimental basis of intraperitoneal chemotherapy. Doctoral thesis, Free University, Amsterdam

    Google Scholar 

  24. Los G, Mutsaers PHA, Vjgh WJF van der, Baldew GS, Graaf PW de, McVie JG (1989) Direct diffusion ofcis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 49: 3380

    Google Scholar 

  25. McKay K (1993) New techniques in the pharmacokinetic analysis of cancer drugs II. The ultratrace determination of platinum in biological samples by inductively coupled plasma-mass spectrometry. Cancer Surv 17: 407

    Google Scholar 

  26. Nichols CR, Williams SD, Loehrer PJ, Greco FA, Crawford ED, Weetlaufer J, Miller ME, Bartolucci A, Schachter L, Einhorn LH (1991) Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9: 1163

    Google Scholar 

  27. Nygren O, Vaughan GT, Florence TM, Morrison GMP, Warner IM, Dale LS (1990) Determination of platinum in blood by adsorptive voltammetry. Anal Chem 62: 1637

    Google Scholar 

  28. Poirier MC, Lippard SJ, Zwelling LA, Ushay HM, Kerrigan D, Thill CC, Santella RM, Grunberger D, Yuspa SH (1982) Antibodies elicited againstcis-diamminedichloroplatinum(II)-modified DNA are specific forcis-diamminedichloroplatinum(II)-DNA adducts formed in vivo and in vitro. Proc Natl Acad Sci USA 79: 6443

    Google Scholar 

  29. Poirier MC, Reed E, Litterst CL, Katz D, Gupta-Burt S (1992) Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. Cancer Res 52: 149

    Google Scholar 

  30. Poirier MC, Shamkhani H, Reed E, Tarone RE, Gupta-Burt S (1992) DNA adducts induced by platinum drug chemotherapeutic agents in human tissues. In: D'Amato R, Slaga TJ, Farland W, Henry C (eds) Relevance of animal studies to the evaluation of human cancer risk. Wiley-Liss, New York, p 197

    Google Scholar 

  31. Reed E, Litterst CL, Thill CC, Yuspa SH, Poirier MC (1987)cis-Diamminedichloroplatinum(II)-DNA adduct formation in renal, gonadal and tumor tissues of male and female rats. Cancer Res 47: 718

    Google Scholar 

  32. Reed E, Ostchega Y, Steinberg SM, Yuspa SH, Young RC, Ozols RF, Poirier MC (1990) Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients. Cancer Res 50: 2256

    Google Scholar 

  33. Singh G (1991) MtDNA as a critical target for cisplatin-induced nephrotoxicity. Proceedings, 6th international symposium on platinum and other metal coordination compounds in cancer chemotherapy, San Diego, CA, USA, January 23–26, 1991, p 284

  34. Stewart DJ, Benjamin RS, Luna M, Feun L, Caprioli R, Seifert W, Loo TL (1982) Human tissue distribution of platinum aftercis-diamminedichloroplatinum. Cancer Chemother Pharmacol 10: 51

    Google Scholar 

  35. Sunderman FW Jr, Sporn J, Hopfer SM, Sweeney KR, Chakraborty NG, Greenberg B (1990) Platinum in blood mononuclear cells from patients after cisplatin therapy. Ann Clin Lab Sci 20: 379

    Google Scholar 

  36. Terheggen PMAB, Floot BGJ, Scherer E, Begg AC, Fichtinger-Schepman AMJ, Engelse L den (1987) Immunocytochemical detection of interaction products ofcis-diammindichloroplatinum(II) andcis-diammine (1,1-cyclobutanedicarboxylato) platinum(II) with DNA in rodent tissues. Cancer Res 47: 6719

    Google Scholar 

  37. Uozumi J, Ueda T, Yasumasu T, Koikawa Y, Naito S, Kumazawa J, Sueishi K (1993) Platinum accumulation in the kidney and liver following chemotherapy with cisplatin in humans. Int Urol Nephrol 25: 215

    Google Scholar 

  38. Vadiei K, Siddik ZH, Khokhar AR, Al-Baker S, Sampedro F, Perez-Soler R (1992) Pharmacokinetics of liposome-entrappedcis-bis-neodecanoato-trans-R-R-1,2-diamminocyclohexane platinum(II) and cisplatin given i.v. and i.p. in the rat. Cancer Chemother Pharmacol 30: 365

    Google Scholar 

  39. Vermorken JB, Vijgh WJF van der, Klein I, Hart AAM, Gall HE, Pinedo HM (1984) Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin. Cancer Treat Rep 68: 505

    Google Scholar 

  40. Vermorken JB, Vijgh WJF van der, Klein I, Gall HE, Groeningen CJ van, Hart GAM, Pinedo HM (1986) Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin Pharmacol Ther 39: 136

    Google Scholar 

  41. Wennerberg J, Biörklund A, Tropé C (1988) The effect of cisplatin and fluorouracil on xenografted human squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 114: 162

    Google Scholar 

  42. Wolf W, Manaka RC (1976) Synthesis and distribution of195mPtcis-dichlorodiammineplatinum(II). J Clin Hematol Oncol 7: 79

    Google Scholar 

  43. Yasumasu T, Ueda T, Uozumi J, Mihara Y, Koikawa Y, Kumazawa J (1992) Ultrastructural alterations and DNA synthesis of renal cell nuclei following cisplatin or carboplatin injection in rats. J Pharm Pharmacol 44: 885

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, University Hospital, S-221 85, Lund, Sweden

    Anders Johnsson, Christina Olsson & Eva Cavallin-Stahl

  2. National Institute of Occupational Health, Umea, Sweden

    Olle Nygren

  3. Department of Occupational Medicine, University Hospital, S-221 85, Lund, Sweden

    Marianne Nilsson

  4. Hospital Pharmacy, University Hospital, S-221 85, Lund, Sweden

    Birgitta Seiving

Authors
  1. Anders Johnsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christina Olsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Olle Nygren
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marianne Nilsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Birgitta Seiving
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eva Cavallin-Stahl
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Johnsson, A., Olsson, C., Nygren, O. et al. Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts. Cancer Chemother. Pharmacol. 37, 23–31 (1995). https://doi.org/10.1007/BF00685625

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00685625

Key words

Search

Navigation